Prediction of response to neoadjuvant chemotherapy: New biomarker approaches and concepts

Breast Care

Volumn 6, Issue 4, 2011, Pages 265-272

  Denkert, Carsten ^a   Sinn, Bruno Valentin ^a   Issa, Yasmin ^b   Müller, Berit Maria ^a   Maisch, Andrea ^b   Untch, Michael ^c   Von Minckwitz, Gunter ^b   Loibl, Sibylle ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Breast Group   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

Breast cancer; Chemotherapy; Lymphocytes; Neoadjuvant; PARP

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HEMATOXYLIN; INITIATION FACTOR 4E BINDING PROTEIN 1; KI 67 ANTIGEN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROGESTERONE RECEPTOR; RNA; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; BREAST CANCER; CANCER RESEARCH; CELL POPULATION; CHEMOSENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GERMANY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MOLECULAR TYPING; NECROSIS; OVARY CANCER; PATHOLOGIST; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SCORING SYSTEM; TISSUE MICROARRAY; TREATMENT RESPONSE;

EID: 80052883298     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000331696     Document Type: Review

References (63)

1. National Cancer Institute: Surveillance Epidermiology and End Results 2008. www.seer.cancer.gov.
2. Jemal A, Siegel R, Xu J, et al.: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V.: Atlas der Krebsinzidenz und Krebsmortalität 2010. www.gekid.de/.
4. Mauri D, Pavlidis N, Ioannidis J, et al.: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188-194. (Pubitemid 40277368)
5. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al.: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24:1940-1949. (Pubitemid 46638994)
6. Arbeitsgemeinschaft Gynäkologische Onkologie: www.ago-online.de/g ('Leitlinien').
7. Kuerer HM, Newman LA, Smith TL, et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469. (Pubitemid 29075229)
8. von Minckwitz G, Blohmer JU, Raab G, et al.: In vivo chemosensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: the GeparTrio pilot study. Ann Oncol 2005;16:1556-1563.
9. von Minckwitz G, Raab G, Caputo A, et al.: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GeparDuo study of the German Breast Group. J Clin Oncol 2005;23:2676-2685. (Pubitemid 46179457)
10. Von Minckwitz G, Kaufmann M, Kümmel S, et al.: Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. J Clin Oncol 2011;29(suppl):abstr 1028.
11. Untch M, Fasching AP, Konecny EG, et al.: Pathological complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in HER2-overexpressing breast cancer - Results from the TECHNO trial of the AGO and GBG study groups. Cancer Res 2010;70(suppl 2):abstr P1-11-03, pg 165s.
12. Liedtke C, Mazouni C, Hess KR, et al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281.
13. Von Minckwitz G, Untch M, Nüesch E, et al.: Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011;125:145-156.
14. Von Minckwitz, Kümmel S, Vogel P, et al.: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100:542-551.
15. Von Minckwitz, Kümmel S, Vogel P, et al.: Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100:552-562.
16. Huober J, von Minckwitz G, Denkert C, et al.: Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010;124:133-140.
17. Von Minckwitz G, Eidtmann H, Rezai M, et al.: Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GeparQuinto study (GBG 44). Cancer Res 2011;70(suppl 2):SABCS10 abstr S4-6.
18. Gerber B, Eidtmann H, Rezai M, et al.: Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: Secondary endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol 2011;29:(suppl): abstr 1006.
19. Bear HD, Tang P, Rastogi P, et al.: The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol 2011;29(suppl):abstr LBA1005.
20. Untch M, Loibl S, Bischoff J, et al.: Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the Gepar-Quinto study (GBG 44). Cancer Res 2010;70(suppl 2):SABCS10 abstr S3-1.
21. Holmes FA, Nagarwala YM, Espina VA, et al.: Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. J Clin Oncol 2011;29(suppl):abstr 506.
22. Loibl S, Bruey J, von Minckwitz G, et al.: Validation of p95 as a predictive marker for trastuzumabbased therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study. J Clin Oncol 2011;29(suppl):abstr 530.
23. Perez EA, Dueck AC, Reinholz MM, et al.: Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. J Clin Oncol 2011;29(suppl):abstr 10504.
24. Dave B, Migliaccio I, Gutierrez MC, et al.: Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011;29:166-173.
25. Huober J, Loibl S, Untch M, et al.: New molecular biomarkers for resistance to trastuzumab-based therapy in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Res 2010;70(suppl 2):SABCS10 abstr PD0206.
26. Kuefer R, Hofer MD, Gschwend JE, Rubin MA: Tissue-Microarrays. Urologe A 2004;43:659-668.
27. Darb-Esfahani S, Loibl S, Müller BM, et al.: Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 2009;11:R69.
28. Denkert C, Loibl S, Roller M, et al.: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:105-113.
29. Noske A, Loibl S, Darb-Esfahani S, et al.: Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat 2011;126:109-117.
30. von Minckwitz G, Müller BM, Loibl S, et al.: Cytoplasmic PARP expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011;29:2150-2157.
31. Bohmann K, Hennig G, Rogel U, et al.: RNA extraction from archival formalin-fixed paraffinembedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 2009;55:1719-1727.
32. Müller BM, Kronenwett R, Hennig G, et al.: Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalinfixed paraffin-embedded tissue - a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol 2011;20:1-10.
33. Darb-Esfahani S, Wirtz RM, Sinn BV, et al.: Estrogen-receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue. Endocr Relat Cancer 2009;16:1229-1239.
34. Sørlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874. (Pubitemid 32878711)
35. Sorlie T, Wang Y, Xiao C, et al.: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006; (7): 127.
36. Calza S, Hall P, Auer G, et al.: Intrinsic molecular signature of breast cancer in a populationbased cohort of 412 patients. Breast Cancer Res 2006;8:R34.
37. Ciocca DR, Gago FE, Fanelli MA, et al.: Coexpression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications. J Steroid Biochem Mol Biol 2006;102:32-40. (Pubitemid 44750632)
38. Prat A, Baselga J: The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with coexpression of HER2. Nat Clin Pract Oncol 2008;5:531-542.
39. Rakha EA, Tan DS, Foulkes WD, et al.: Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res 2007;9:404.
40. Chalmers AJ: The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009;89:23-40.
41. Bernstein C, Bernstein H, Payne CM, et al.: DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002;511:145-178. (Pubitemid 34621252)
42. Fisher AEO, Hochegger H, Takeda S, et al.: Poly (ADP-ribose) polymerase 1 accelerates singlestrand break repair in concert with poly (ADP-ribose) glycohydrolase. Mol Cell Biol 2007;27:5597-5605. (Pubitemid 47124411)
43. Audebert M, Salles B, Calsou P: Involvement of poly (ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004;279:55117-55126. (Pubitemid 40066505)
44. Chang P, Jacobson MK, Mitchison TJ: Poly (ADP-ribose) is required for spindle assembly and structure. Nature 2004;432:645-649. (Pubitemid 39626273)
45. Kim MY, Mauro S, Gevry N, et al.: NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 2004;119:803-814. (Pubitemid 40017687)
46. Woodhouse BC, Dianov GL: Poly ADP-ribose polymerase-1: An international molecule of mystery. DNA Repair 2008;7:1077-1086.
47. Rowe BP, Glazer PM: Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res 2010;12:203.
48. O'Shaughnessy J, Osborne C, Pippen JE, et al.: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-214.
49. Annunziata CM, O'Shaughnessy J: Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 2010;16:4517-4526.
50. Smith IC, Heys SD, Hutcheon AW, et al.: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-1466. (Pubitemid 34260523)
51. Fisher B, Bryant J, Wolmark N, et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685. (Pubitemid 28363030)
52. Rastogi P, Anderson SJ, Bear HD, et al.: Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-785. (Pubitemid 351264391)
53. Zitvogel L, Kroemer G: The immune response against dying tumor cells: avoid disaster, achieve cure. Cell Death Differ 2008;15:1-2. (Pubitemid 350286166)
54. Apetoh L, Ghiringhelli F, Tesniere A, et al.: The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007;220:47-59. (Pubitemid 350045573)
55. Apetoh L, Tesniere A, Ghiringhelli F, et al.: Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008;68:4026-4030.
56. Zitvogel L, Apetoh L, Ghiringhelli F, et al.: Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59-73.
57. Zitvogel L, Apetoh L, Ghiringhelli F, et al.: The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008;118:1991-2001. (Pubitemid 351872317)
58. Apetoh L, Ghiringhelli F, Tesniere A, et al.: Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-1059. (Pubitemid 47517504)
59. Pagès F, Berger A, Camus M, et al.: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-2666. (Pubitemid 41817714)
60. Zhang L, Conejo-Garcia JR, Katsaros D, et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213. (Pubitemid 36077915)
61. DeNardo DG, Coussens LM: Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007;9:212.
62. Aaltomaa S, Lipponen P, Eskelinen M, et al.: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992;28:859-864.
63. Schmidt M, Böhm D, von Törne C, et al.: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405-5413.